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Background: Because circulating antibodies against a variety of antigens have been detected in patients with
coronary heart disease, carotid atherosclerosis and those who have suffered a stroke, it is suspected that immune
response may be one of the mechanisms of atherogenesis The objective of this study is to identify novel
antibodies in ischemic stroke patients by screening the expressed recombinant proteins using a human cDNA
library (SEREX).
Methods: To identify the candidate antigens, cDNA library was screened by SEREX using plasma from ten patients
with ischemic stroke. Subsequently, via ELISA using recombinant proteins and synthetic peptides, the serum
antibody levels were measured in two independent patient/healthy donor (HD) cohorts (142 and 78 in the 2nd
screening and a validation cohort, respectively).
Results: The initial screening resulted in the identification of six candidate antigens. Of these antigens, replication
protein A2 (RPA2) was determined to be the antigen associated with stroke (P < 0.05) by ELISA with 2nd screening
and validation cohort. Multifactorial logistic regression analysis showed that the increased levels of the RPA2
antibodies (RPA2-Abs) associated with stroke independent of other risk factors for stroke (P < 0.05). Receiver
operating curve analysis demonstrated that the area under the curve from ELISA using GST fusion RPA2 and
synthetic peptides (bRPA2-132) were 0.867 (95% CI: 0.798-0.936) and 0.971 (95% CI: 0.940-1.00), respectively. If the
cut-off value of the bRPA2-132-Ab level was determined to be 0.334, the sensitivity and specificity of the antibody
level as the diagnostic marker for stroke were 0.323 (95% CI: 0.209-0.453) and 1.00 (95% CI: 0.713-1.00), respectively.
Conclusions: SEREX identified RPA2 as the antigen associated with ischemic stroke and serum auto-antibodies
against RPA2 elevates in stroke patients. RPA2-Abs could become a biomarker for the evaluation of ischemic stroke
at risk.
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Current studies recognize the role of inflammation in all
stages of atherosclerosis and, subsequently, the immune
system has become a subject of focus in this field [1].
Both innate and adoptive immunities, which recognize
endogenous antigens such as proteins, carbohydrates,
lipids and nucleic acids, influence the progression of* Correspondence: hiwasa_takaki@faculty.chiba-u.jp
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unless otherwise stated.atherosclerosis [2]. The proposed antigenic proteins that
evoke immune responses and affect this progression in-
clude oxidized-low density lipoprotein (oxLDL), phos-
phorylcholine, heat shock proteins (Hsps), apo-A1 and
phospholipids as well as the antibodies for these anti-
gens, all of which have been found in elevated levels in
patients diagnosed with a cardiovascular disease [3]. Is-
chemic stroke is the major cause of worldwide mortality
and morbidity and one of the primary mechanisms of
stroke is atherosclerosis. Along with other cardiovascular
diseases, the increased antibody levels for antigens suchl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ischemic stroke [3].
Serological identification of antigens by recombinant
cDNA expression cloning (SEREX) is an approach to
antigenic protein identification that enables large-scale
screening [4]. Although originally developed to screen
cancer-associated antigens, this method has also been
applied to vascular conditions such as transplant-
associated coronary artery disease [5], Kawasaki disease
[6], and moyamoya disease [7]. To our knowledge,
stroke-associated antigens have not been screened for.
Based on the notion that antigens other than Hsps are
implicated in stroke, we screened a human microvascu-




This study is as a part of the Genomic and Proteomic
Research for Stroke Study at Chiba University Graduate
School of Medicine. The Local Ethical Review Board of
Chiba University Graduate School of Medicine approved
the study and written informed consent was obtained
from each subject. The inclusion criteria of the patients
is those who suffered ischemic stroke and admitted to
three participant hospitals within two weeks from the
stroke onset. Healthy donors (HDs) were collected from
those who undergo medical checkup and all of them
were without history of ischemic stroke. Those with an
autoimmune disease were excluded from this study. The
population of this study consists of three independent
patient/HD cohorts: a 1st, a 2nd and validation cohort
(Table 1). Ten patients with ischemic stroke due toTable 1 Baseline characteristics of subjects in 1st, 2nd and va
1st Screening 2nd Screening
Patients (n = 10) Patients (n = 134
Age 72.4 (3.53) 68.1 (10.4)
Male gender 9 (90) 106 (79.3)
Hypertension 6 (60) 88 (65.9)
Diabetes 3 (30) 35 (25.9)
Hyperlipidemia 3 (30) 36 (26.7)
Smoking 1 (10) 46 (34.1)
Stroke 10 (100) 129 (96.3)
Stroke etiology
LAA 10 (100) 34 (21.5)
SVD 0 (0) 62 (39.2)
CE 0 (0) 14 (8.9)
UD and others 0 (0) 24 (15.2)
Carotid stenosis >50% 10 (100) 31/102 (30.4)
Baseline characteristics of subjects in 1st, 2nd and validation cohort are displayed. D
CE, cardioembolism. HD, healthy donor. N/A, not assessed. LAA, large artery atherossevere (>90%) carotid stenosis were selected for the 1st
screening cohort and remaining 142 and 78 patient/HD
were allocated to 2nd screening and validation cohort,
respectively. In order to discuss the relations between
the antibody levels and the severity of atherosclerosis,
those with known carotid stenosis were preferentially al-
located to 2nd screening cohort and thus, among 154
patients in the two cohorts, 37/102 (30.4%) and 1/26
(3.84%) had significant (>50%) carotid stenosis in the
2nd and validation screening cohort, respectively.
Blood sampling and purification
Blood samples were collected both with and without
EDTA from each patient upon admission, centrifuged at
3000 × g for 10 min at room temperature and the super-
natant was stored at −80°C. Plasma and serum were
used in the screening of the 1st and the 2nd/validation
cohorts, respectively.
Clinical data
Classical risk factors for atherosclerosis, including gen-
der, age, incidence of hypertension, diabetes, hyperlipid-
emia, and cigarette smoking, were evaluated from
clinical records. Hypertension was defined as a history
of blood pressure above 140 mmHg in systolic or
90 mmHg in diastolic pressure or the use of antihyper-
tensive agents. Diabetes was defined as having under-
gone antidiabetic therapy or having a history of diabetes.
Hyperlipidemia was defined as having a history of total
cholesterol > 220 mg/dl or triglyceride > 150 mg/dl or
the use of lipid lowering drugs. Patients were considered
smokers if they currently smoked or had a history of
smoking. Angiographic stenosis rates were determinedlidation cohort
Validation
) HD (n = 24) Patients (n = 70) HD (n = 42)
64.4 (8.03) 68.6 (10.3) 53.0 (4.57)
21 (87.5) 54 (77.1) 25 (59.5)
1 (4.17) 45 (64.3) N/A
3 (12.5) 17 (24.3) N/A
1 (4.17) 22 (31.4) N/A
6 (25.0) 24 (34.3) N/A






N/A 38/60 (63.3) N/A
ata represents means (SD) for numerical data and n (%) for categorical data.
clerosis. SVD, small vessel disease. UD, undetermined ethiology.
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American Symptomatic Carotid Endarterectomy Trial
(NASCET) [8] and patients were categorized as having
significant carotid stenosis when the blockage exceeded
50% by NASCET measurement. The stroke subtype for
each patient was also determined according to the cri-
teria of the Trial of Org 10172 in Acute Stroke Treat-
ment classification system [9].
SEREX screening of cDNA libraries
Recombinant DNA studies were performed with the offi-
cial permission of the Chiba University Graduate School
of Medicine and were carried out in accordance with the
rules of the Japanese government. We used a commer-
cially available human microvascular endothelial cell
cDNA library (Uni-ZAP XR Premade Library, Stratagene,
La Jolla, CA) to screen for clones that were immunore-
active against plasma from patients with severe carotid
stenosis. The screening method used in this study is a
modification of a published procedure as described previ-
ously [10-12]. Escherichia coli XL1-Blue MRF’ was in-
fected with Uni-ZAP XR phage and the expression of
resident cDNA clones was induced after blotting the in-
fected bacteria onto NitroBind nitrocellulose membranes
(Osmonics, Minnetonka, MN) that had been treated
with 10 mM isopropyl-β-D-thiogalactoside (Wako Pure
Chemicals, Osaka, Japan) for 30 min. The membranes
with bacterial proteins were washed 3 times with TBS-T
[20 mM Tris–HCl (pH 7.5), 0.15 M NaCl and 0.05%
Tween-20], and non-specific binding was blocked by incu-
bation with 1% protease-free BSA (Wako Pure Chemicals)
in TBS-T for 1 h. The membranes were exposed to
1:2000-diluted plasma for 1 h. The pre-absorption of
plasma antibodies against bacterial proteins is a routine
procedure [4]. However, because cross-reactive antibodies
to bacterial and human proteins are possible antigens in
the case of atherosclerosis, we screened the samples with-
out pre-absorption. After 3 washes with TBS-T, the mem-
branes were incubated for 1 h with 1:5000-diluted alkaline
phosphatase-conjugated goat anti-human IgG (Jackson
ImmunResearch Laboratories, West Grove, PA). Positive
reactions were developed using 100 mM Tris–HCl
(pH 9.5), containing 100 mM NaCl, 5 mM MgCl2,
0.15 mg/ml of 5-bromo-4-chloro-3-indolylphosphate
and 0.3 mg/ml of nitro blue tetrazolium (Wako Pure
Chemicals). Positive clones were re-cloned two add-
itional times in order to obtain monoclonality.
Sequence analysis of identified antigens
Monoclonal phage cDNA clones were converted to
pBluescript phagemids by excision in vivo using the
ExAssist helper phage (Stratagene). Plasmid DNA was
obtained from the E. coli SOLR strain after transform-
ation by the phagemid. The cDNA insertions weresequenced by dideoxy chain termination using DNA Se-
quencing BigDye Terminator Kits (Applied Biosystems,
Foster City, CA) and an ABI PRISM 3700 DNA Analyzer
(Applied Biosystems). Sequences were screened for hom-
ology with identified genes or proteins within the public
sequence database using the NCBI-BLAST algorithm
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Expression and purification of antigenic GST-fusion proteins
Recombinant proteins tagged with glutathione-S-transferase
(GST) were constructed by recombining the insertion se-
quences of pBluescript into pGEX-4T (GE Healthcare Life
Sciences, Pittsburgh, PA) vector plasmids. The pBluescript
plasmids were digested using a combination of EcoRI and
XhoI or SmaI and XhoI. The inserted DNA fragments
were isolated using GeneElute™ Minus EtBr SPIN COL-
UMNS (Sigma-Aldrich, St. Louis, MO). The insertion se-
quences were ligated in frame to SmaI- and XhoI-digested
pGEX-4T-1 or EcoRI- and XhoI-digested pGEX-4T-3
using Ligation Convenience Kits (Nippon Gene, Toyama,
Japan). The ligation mixtures were used to transform
ECOS™ competent E. coli JM-109 (Nippon Gene) and ap-
propriate recombinants were confirmed by DNA sequen-
cing. The constructed pGEX recombinants with the
correct insertion in the right orientation were then used to
transform competent E. coli BL21-RIL-codon-plus (Strata-
gene). The expression of the GST-fusion proteins was in-
duced by treating the transformed E. coli with 0.1 mM
isopropyl-β-D-thiogalactoside for 3 h. The GST recombin-
ant proteins were purified by glutathione-Sepharose col-
umn chromatography according to the manufacturer’s
instructions (GE Healthcare Life Sciences) and dialyzed
against 1 mM Tris–HCl (pH 7.5) and 1 mM EDTA.
SDS-PAGE and Western blotting
To confirm the recombinant proteins to be the GST-
tagged one that react with autologous plasma, the pro-
teins were lysed in a SDS sample buffer, incubated at
100°C for 3 min, resolved by 12% SDS-polyacrylamide
gel electrophoresis (PAGE) and Western blotted. The
blotted proteins were probed with an autologous plasma
by which the protein was identified or with goat anti-
GST polyclonal antibody (Rockland, Gilbertsville, PA).
Anti-RPA2 monoclonal antibody (Oncogene Research
Products, San Diego, CA) was used to confirm the pres-
ence of purified GST-tagged RPA2.
Quantitative measurement of serum antibodies against
purified proteins by ELISA
Ninety-six-well microtiter plates were coated overnight
with 50 μl of 1.5 μg/ml of goat anti-GST antibody
(Rockland) in a 0.05 M carbonate/bicarbonate buffer
(pH 9.6). The plates were blocked with 150 μl of 1%
nonfat dry milk in phosphate-buffered saline (PBS) for
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and incubated with 50 μl of purified antigens (10 μg/ml) in
PBS-T. Plates were left overnight at 4°C. After 4 washes
with PBS-T, 50 μl of serum diluted at 1:200 in a blocking
buffer were added to each well and incubated for 2 h.
Thereafter, the plates were washed 4 times with PBS-T and
exposed to 50 μl of horseradish peroxidase-conjugated
anti-human IgG Ab (Jackson) diluted at 1:10,000 in block-
ing buffer for 45 min at room temperature. Plates were
then washed 4 times with PBS-T, developed with 100 μl of
400 μg/ml of o-phenylene diamine (Sigma-Aldrich) in a
0.1 M phosphate-citrate buffer (pH 4.5) for 20 min and
stopped by adding 30 μl of 8 N H2SO4. Absorbance at
490 nm was determined using a microplate reader (Emax,
Molecular Devices, Sunnyvale, CA). Each blood sample
was tested in duplicate against GST-antigen fusion protein
or control GST alone from a non-recombinant pGEX vec-
tor. GST-tagged WD repeat 36 protein diluted at 1:200,
1:400, 1:800 and 1:1600 versus patient No. 8 was the
standard in each plate. After normalization by the stan-
dards, the levels of serum antibody were calculated by sub-
tracting the absorbance of serum against GST from that
against GST-tagged antigens as described previously [11].
Peptide synthesis and ELISA
Three epitope sites in RPA2 protein were predicted using
the program ProPred (http://www.imtech.res.in/raghava/
propred/). Three N-terminal biotinylated peptides were
synthesized and used as antigens to examine the antibody
levels by ELISA. The amino acid sequence of each peptide
was as follows:
 bRPA2-74; biotin-VTIVGIIRHAEKAPT (amino acids
between positions 74 and 88)
 bRPA2-90; biotin-VYKIDDMTAAPM (amino acids
between positions 90 and 102)
 bRPA2-132; biotin-LRSFQNKKSLVAFKI (amino
acids between positions 132 and 146)
The purities of bRPA2-74, bRPA2-90 and bRPA2-132
were 96%, 98% and 93%, respectively. The ELISA plates
were pretreated with 10 μg/ml of streptavidin in a 0.05 M
carbonate/bicarbonate buffer (pH 9.6). After blocking, the
plates were incubated with 50 μl of the peptides (100 μg/ml)
in PBS-T.
Immunohistochemistry
Tissue samples were obtained from surgically resected
carotid atherosclerotic plaque. The samples were fixed
with formalin and embedded in paraffin. The samples
were pretreated by heating them in a microwave in a cit-
rate buffer for 10 min at 500 W. The first antibodies
used were the monoclonal anti-human RPA2 antibody
(Santa Cruz Biotechnology), the anti-CD68 antibody(Santa Cruz) and the anti-SMC (smooth muscle cells)
antibody (Santa Cruz) at a dilution of 1:100. After incu-
bation at 37°C for 60 min, the specimens were incubated
with biotin-labeled rabbit anti-mouse-IgG secondary anti-
body and, next, with streptavidin-labeled peroxidase. Sec-
tions were counter-stained with hematoxylin after the
DAB reaction as described in the literature [12].Statistical analysis
Data were processed using EZR software [13]. Differences
between numerical and categorical data with respect to
each group were assessed using the Mann–Whitney U or
Kruskal-Wallis test and the chi-square test, respectively.
Correlation between the numerical data was assessed by
linear regression analysis. Multivariate logistic regression
analysis was used to find a set of variables classifying the
subjects into those with and without a history of stroke.
The predictive value of RPA2-Abs for stroke was assessed
by receiver operating curve (ROC) analysis and the cut-off
values of RPA2-Ab levels were set at the values that
maximize the sums of the sensitivity and specificity. All
tests were two-tailed and a P value below 0.05 was consid-
ered significant.Results
Primary screening by SEREX
We screened 8 × 106 cDNA clones using plasma from ten
patients with ischemic stroke caused by severe carotid
stenosis (>90%) and isolated 6 reactive clones (Figure 1A,
Table 2). DNA sequence analysis and a subsequent hom-
ology search of accessible NCBI databases showed that all
6 clones were independent. These clones were further an-
alyzed by Western blotting and ELISA.SDS-PAGE and Western blots of purified antigens
To purify the SEREX-identified proteins, the insertion
sequences of the 6 pBluescript plasmids were ligated
in-frame into GST-tagged expression vectors. We con-
firmed by sequence analysis that the recombinant
pGEX-4T plasmids were properly recombined and
GST-tagged recombinant proteins were affinity-purified
using glutathione-Sepharose. Purified proteins were re-
solved by SDS-PAGE and then either directly stained
with Coomassie Blue (Figure 1B, lane 1) or Western
blotted against the anti-GST antibody (Figure 1B, lane
2) or the autologous plasma antibody (Figure 1B, lane
3). Almost all of the Coomassie-stained bands were rec-
ognized by anti-GST antibody (lanes 1 and 2), indicat-
ing that they are GST-antigen fusion proteins and the
respective degradation products. The molecular weight
of the largest product was similar to that predicted by
sequencing analysis.
AB
BMP1 LGALS9 PPP1R15A RPA2 SC5 WD36
1      2       3           1     2       3         1       2     3        1       2       3         1      2       3       1 2      3
60kDa
27kDa
Figure 1 1st screening by SEREX and Western blot analysis. Recombinant proteins were blotted onto NitroBind nitrocellulose membranes
and reacted with patient plasma (arrow head). (A) Affinity-purified GST-tagged antigens were separated on 12% SDS-polyacrylamide gels stained
with Coomassie staining (lane 1), or Western blotted using anti-GST antibody (lane 2) or autologous sera (lane 3) (B).
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antigens
To determine whether the six candidate antigens are
atherosclerosis-related, we first studied the relations be-
tween the antibody levels and the degree of carotid ath-
erosclerosis in the 2nd screening cohort. Of the six
candidate antigens, only the antibody against replication
protein A2 (RPA2) levels was significantly higher in pa-
tients with significant carotid stenosis (≥50%) than those
with less advanced lesions (P < 0.05) (Figure 2E), and we
further analyzed the relationship between antibodies
against RPA2 (RPA2-Ab) levels and other clinical param-
eters. The RPA2-Ab level is weakly associated with age
(r2 = 0.113, P < 0.05, Figure 3A) with levels significantly
higher in those with hypertension (P < 0.05, Figure 3C).
On the other hand, there was no significant difference of
the RPA2-Ab levels regarding other parameters including
sex, diabetes, hyperlipidemia, smoking, intracranialTable 2 Genes identified by SEREX
Clone name Gene identity Accession No.
CU-CA-1 BMP1 NM_006129
CU-CA-14 LGALS9 NM_002308
CU-CA-23 PPP1R15A BC 003067
CU-CA-26 RPA2 NM_002946
CU-CA-28 SC65 BC 007942
CU-CA-35 WD36 NM_139281
Six independent clones were identified by SEREX using plasma from a patient
with ischemic stroke caused by severe carotid stenosis (>90%).stenosis, infarct size and timing of blood sampling
(Figure 3B, D, E, F, I, J and K). Interestingly, the in-
creases in the antibody levels in stroke patients (Figure 3G)
was more prominent than those in patients with carotid
stenosis (Figure 2E) and the antibody levels elevate
in stroke patients irrespective of the stroke subtype
(Figure 3H). These results suggest that the RPA2-Abs asso-
ciate more strongly with ischemic stroke than atheroscler-
osis. Therefore, we further analyzed the predictive value of
RPA2-Abs for the diagnosis of ischemic stroke. Receiver
operating curve (ROC) analysis revealed that the area
under the curve (AUC) was 0.867 (95% CI: 0.798-0.936)
(Figure 4A). If the cut-off value of the RPA2-Ab level
was determined to be 0.275, the sensitivity and specifi-
city of the antibody level for the diagnosis of stroke
were 0.703 (95% CI: 0.612-0.784) and 0.917 (95% CI:
0.730-0.990), respectively (Figure 4A and E). Univariate
and multivariate logistic regression analysis revealed
that, among the other risk factors for stroke, the digita-
lized RPA2-Ab level was independently and strongly as-
sociated with ischemic stroke (O.R.:18.1, 95% CI: 3.10-
106, P < 0.01) (Table 3).
Validation of elevated p-RPA2-Abs levels in stroke
patients using synthetic peptides
To validate the elevated levels of RPA2-Abs in stroke pa-
tients and to identify the antigenic epitopes of RPA2, we
further examined the RPA2-Abs levels using synthetic
peptides in the independent validation cohort (n =78).
Three synthetic peptides corresponding to the predicted
A PPP1R15A B BMP1 C LGALS9
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Figure 2 Second screening by ELISA. Antibody levels against six candidate antigens were compared between patients with and without >50%
carotid stenosis by ELISA (A-F). Only the antibody levels against GST-tagged RPA2 were significantly higher in patients with carotid stenosis (E).
*P < 0.05 by Mann–Whitney U test. CS, carotid stenosis. Ab, antibody.
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the serum antibody levels. bRPA2-74 with amino acid
sequence 74–88 showed lower antibody levels in pa-
tients with ischemic stroke as compared with the levels
in HD (Figure 4B). On the other hand, bRPA2-90 and
bRPA2-132 with amino acid sequences 90–102 and
132–146, respectively, showed significantly higher levels
in the patients than those in HD (Figure 4C and D). The
predictive values of the antibody levels against the three
peptides were evaluated by ROC analysis (Figure 4B and D).
The AUCs of bRPA2-74, bRPA2-90 and bRPA2-132 were
0.812 (95% CI: 0.702-0.813), 0.928 (95% CI: 0.874-0.982)
and 0.971 (95% CI: 0.940-1.00) for each. If the cut-off
value of the bRPA2-132-Ab level was determined to be
0.334, the sensitivity and specificity of RPA2-Ab level for
the diagnosis of stroke were 0.323 (95% CI: 0.209-0.453)
and 1.00 (95% CI: 0.713-1.00), respectively.
Immunohistochemistry
We also examined RPA2 protein expression in surgically-
resected carotid atherosclerotic plaque using immuno-
histochemistry. RPA2 was predominantly expressed in the
intima of atherosclerotic plaque (Figure 5D). The expres-
sion of RPA2 was closely co-localized with CD68-positivemacrophages (Figure 5C) but not with smooth muscle
cells (Figure 5B).
Discussion
Much evidence indicates that the immune system is in-
volved in atherogenesis. Atherosclerotic lesions contain
significant amounts of macrophages and activated T cells
[14-16], suggesting that both innate and adaptive types
of immunity are involved in lesion development. Anti-
gens that might activate immune responses are oxLDL,
phosphorylcholine, heat shock proteins (Hsps), apo-A1
and phospholipids [3]. Subsequent clinical studies have
demonstrated that serum antibodies against these anti-
gens are found in increased quantities in patients with
atherosclerotic vascular diseases such as myocardial in-
farction, carotid atherosclerosis and ischemic stroke and
have assessed the role of auto-antibodies as prognostic
biomarkers of plaque vulnerability [17-21].
Thus, immune involvement in atherogenesis has been
studied in detail, whereas to our knowledge the antigens
related to atherosclerosis have not been comprehensively
analyzed. Novel antigens might contribute to the diagnosis
and the treatment of stroke. We searched for antigens that
might be involved in stroke using SEREX, which is a
Figure 3 (See legend on next page.)
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Figure 3 Association between antibody against RPA2 and other clinical parameters. The antibody levels against RPA2 weakly correlated
with age (*r2 = 0.113, P < 0.05). Correlation was examined between RPA2-Abs and age (A), gender (B), hypertention (C), diabetes (D), hyperlipidemia
(E), smoking (F), ischemic stroke (G), stroke subtype (H), intracranial stenosis (I), infarct size (J) and period between the onset and blood sampling
(K). The elevated antibody levels were observed in patients with hypertension and ischemic stroke (*P < 0.05 by Mann–Whitney U test). RPA2-Abs,
RPA2 antibodies. LAA, large artery atherosclerosis. SVD, small vessel disease. CE, cardioembolism. HD, healthy donor.
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lated 6 cDNA clones in this manner. Subsequent quantita-
tion of antibody levels by ELISA demonstrated that levels
of RPA2-Abs were elevated in stroke patients and that
these increased levels were independent of the other clas-
sical risk factors for atherosclerosis such as age, hyperten-
sion, gender, diabetes, hyperlipidemia and cigarette
smoking. These results indicate that immunity to RPA2 is
a factor associated with the development of advanced ath-
erosclerosis and ischemic stroke.
Immunity to some antigens, such as oxLDL and Hsps,
has been assumed to be one of the underlying pathome-
chanisms of atherogenesis [17,18]. However, the molecular
pathomechanisms by which these antigens are implicated
in atherogenesis are still not completely understood. The
putative scenario is as follows: LDL particles accumulate
in the extracellular matrix of atherosclerotic plaque and,Figure 4 ROC analysis. Receiver operating curve (ROC) analysis for the ev
(A), bRPA2-4 (B), bRPA2-90 (C) and bRPA2-132 (D). Areas under the curve
0.928 (95% CI: 0.874-0.982) and 0.971 (95% CI: 0.940-1.00), for each antigen.
those in the parentheses indicates specificity (left) and sensitivity (right). Do
purified RPA2 protein (E), bRPA2-4 (F), bRPA2-90 (G) and bRPA2-132 (H). T
calculated in the ROC analysis. *P < 0.05 by Mann–Whitney U test.following modification by enzymatic degradation and oxi-
dation, they are engulfed by macrophages, presented to
CD4+ T-cells, thereby activating an adaptive immune re-
sponse [22]. Antibodies against Hsps of microorganisms,
such as Chlamydia pneumoniae, might cross-react with
human Hsp60 that is overexpressed in the arterial wall by
high arterial shear stresses [23,24]. In the case of RPA,
whether or not it is implicated in atherogenesis remains to
be proved. RPAs are composed of three subunit proteins
of 70, 32, and 14 kDa (RPA1, RPA2, and RPA3, respect-
ively). In the rat brain, DNA double-strand breaks (DSBs)
were induced by ischemia [25], and BRCA1 which is in-
volved in the repair of DNA DSBs has been shown to be
involved in heart function and survival following myocar-
dial infarction [26]. It is noteworthy that the RPA complex
works in the upstream pathway of BRCA1 in the DSB re-
pair pathway [27,28]. In atherosclerotic plaque, cells arealuation of diagnostic value of antibodies against purified RPA2 protein
(AUC) were 0.867 (95% CI: 0.798-0.936), 0.812 (95% CI: 0.702-0.813),
Number in the curves indicate cut-off value of RPA2 Ab level and
t plot of antibody levels in patients and healthy donors against
he horizontal bar indicates the cut-off value for each antibody level
Table 3 Logistic regression analysis for the prediction of stroke in the 2nd screening cohort
Univariate Multivariate
Odds ratio 95% CI P Odds ratio 95% CI P
Age (per year) 1.04 1.00-1.09 0.0513 1.05 0.986-1.11 0.138
Male gender 1.63 0.501-7.01 0.604 - - -
Hypertension 7.93 2.85-25.8 <0.01 4.17 1.36-12.7 <0.05
Diabetes 1.70 0.570-6.17 0.473 - - -
Hyperlipidemia 5.21 1.19-47.55 <0.05 7.47 1.34-41.7 <0.05
Smoking 2.25 0.82- 7.26 0.130 - - -
RPA2-Ab* 11.8 4.39-34.9 <0.01 8.16 2.84-23.4 <0.01
*The levels of RPA2-Abs were digitalized by cut-of value of 0.186 in 2nd cohort.
Machida et al. Journal of Translational Medicine  (2015) 13:71 Page 9 of 11exposed to reactive oxygen species which can provoke ex-
tensive oxidative DNA damage [29,30]. The RPA complex
which is required for DSB repair might be expressed in
higher amount. In fact, a high rate of expression of the
RPA2 protein was observed in the intima of atheroscler-
otic plaque (Figure 5D). The prominence of RPA here may
explain why autoantibody levels are raised against RPA2.
It is also likely that antigen proteins leak out from vascular
lesion by repeated microenvironmental artery destruction,
which frequently happens before the onset of ischemic
stroke. Consistently, RPA2 antibody levels were related to
ischemic strokes (Figure 3G). RPA2 antigen proteins dis-
appeared rapidly, yet the antibodies can be amplified
after repeated exposure to antigen proteins. If we can
detect such antibody markers, the onset of stroke can beFigure 5 Immunohistochemistry. Surgically-excised carotid plaque was s
(C, arrow) or anti-RPA2 antibody (D, arrow head).predicted with a high probability as compared to the pre-
dictive powers of the known risk factors alone. Increasing
novel antibody markers identified by SEREX other than
RPA2 may improve the predictive accuracy for patients
with ischemic stroke.
As mentioned above, we hypothesize that the RPA2-Abs
might originate from the vascular lesion (i.e. atheroscler-
otic plaque) and that the RPA2-Abs might become a bio-
marker for the diagnosis of and, conceivably, for the
prediction of stroke. Because all the blood samplings in
this study were done after the onset of stroke, when the
patients were auto-sensitized to RPA2 is to be proved.
However, because IgG antibodies, which we measured in
this study, develop several weeks after the exposure to the
antigen and because the most of the specimens used intained with hematoxylin only (A), or with anti-SMC (B), anti-CD68
Machida et al. Journal of Translational Medicine  (2015) 13:71 Page 10 of 11the present study were collected within three days from
the onset of stroke, it is plausible that the RPA2-Abs were
produced before the onset of ischemic stroke. The diver-
gent antigenic proteins may appear in the surface of the
vascular lesion and the IgG antibodies against such newly
produced antigens may be produced before the onset of
stroke. And therefore, the RPA2-Abs might be a bio-
marker for the evaluation of stroke at risk rather than the
stroke itself. Further study is needed to elucidate the the
Ab levels before and after the onset of stroke.
Conclusions
We have identified six candidate antibody markers for
ischemic stroke by SEREX screening. ELISA using re-
combinant antigen proteins and synthetic peptides re-
vealed that the antibody levels to RPA2 were higher in
patients with a history of ischemic stroke than in HD,
suggesting that the autoimmunity to RPA2 may play
some role in the pathogenesis of ischemic stroke. Fur-
ther studies are needed to find out whether the elevation
of RPA2 Ab could become a biomarker for the evalu-
ation of ischemic stroke at risk.
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